ABSTRACT:
Introduction
Although cannabis (also called marijuana) remains one of the most abused drugs in the United States (Banken, 2004; Seely et al., 2011 Seely et al., , 2012 , synthetic cannabinoids are gaining popularity among recreational drug users as adulterants of herbal products commonly marketed as "K2" or "Spice" (Kudo et al., 1995; European Monitoring Centre for Drugs and Drug Addiction, 2009; Atwood et al., 2010; Dresen et al., 2010; Seely et al., 2011 Seely et al., , 2012 . [1-naphthalenyl-(1-pentyl-1H-indol-3-yl]-methanone (JWH-018) and [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone (AM2201) represent two common derivatives structurally characterized as aminoalkylindoles (Compton et al., 1992a,b; Atwood et al., 2010) . These derivatives were first synthesized in the early 1990s to study the pharmacology of the cannabinoid type 1 (CB 1 ) receptor, the predominant G-protein-coupled receptor in the brain, and the cannabinoid type 2 (CB 2 ) receptor, located on immune cells (Huffman and Padgett, 2005; Mackie, 2008) . Receptor binding studies have shown JWH-018 (Atwood et al., 2010; Brents et al., 2011) and other aminoalkylindoles to be high-affinity ligands (Ward et al., 1990; Thakur et al., 2005) at CB 1 and CB 2 receptors. Synthetic cannabinoids have potential therapeutic benefits because of their antiemetic and pain-relieving properties (Seely et al., 2011) ; however, most synthetic cannabinoids synthesized to date have not been approved for human use because of toxic side effects and undesirable psychoactive properties (Camp, 2011; Wells and Ott, 2011) .
Whereas use of cannabis, which contains the natural psychoactive cannabinoid ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC), is often associated with mild symptoms such as appetite stimulation and orthostatic hypotension (Jones, 2002; Randall et al., 2004) , K2 users present to emergency departments with severe adverse effects including hypertension, visual and auditory hallucinations, tachycardia, sinus bradycardia, chest pain, dysrhythmias, seizures, psychosis, intracranial hemorrhage, and even death (Mü ller et al., 2010; Vearrier and Osterhoudt, 2010; Benford and Caplan, 2011; Every-Palmer, 2011; Lapoint et al., 2011; Schneir et al., 2011; Simmons et al., 2011a,b; Young et al., 2011; Pant et al., 2012) . In addition, recent medical reports indicate that chronic K2 use may lead to the development of tolerance, dependence, and withdrawal (Zimmermann et al., 2009) , as has been observed with marijuana abuse (Budney and Hughes, 2006) .
Little information is known about the metabolism and pharmacology of these emerging drugs of abuse. We and others have identified several hydroxylated metabolites of JWH-018 and AM2201 in humans with a known history of K2 use, implicating the role of mixedfunction oxidases, such as cytochromes P450, in the biotransformation of synthetic cannabinoids (Zhang et al., 2002; Sobolevsky et al., 2010; Wintermeyer et al., 2010; Chimalakonda et al., 2011b; Hutter et al., 2012) . Previous reports showed that JWH-018 undergoes hepatic metabolism, leading to the formation of several naphthalene, indole, and alkyl side chain hydroxylated and carboxylated metabolites (Fig. 1) , which are subsequently conjugated by UDP-glucuronosyltransferases and excreted as glucuronic acid conjugates in human urine (Chimalakonda et al., 2011a,b) . In addition, a recent study by Brents et al. (2011) demonstrated that the ring and side chain hydroxylated derivatives of JWH-018 possessed greater in vitro and in vivo pharmacological activity than ⌬ 9 -THC, indicating that oxidative biotransformation does not terminate the pharmacological activity of JWH-018. Thus, compared with ⌬ 9 -THC, the increased severity and frequency of adverse effects of K2 may be explained, in part, by the generation of biologically active metabolites that may prolong or intensify CB 1 receptor activation. This important observation exemplifies the necessity for characterizing the specific metabolic pathways responsible for the biotransformation of these new, emerging drugs of abuse.
The purpose of this study was to identify specific P450 isoforms responsible for JWH-018 and AM2201 oxidation and to determine whether primary human -(1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)-methanone) and -1-hydroxylated (1-(4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone) and (1-(5-fluoro-4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone) metabolites FIG. 1. Structures of JWH-018 and AM2201 and hydroxyl metabolites. JWH-018 (1) and AM2201 (2) are structurally similar, with AM2201 differing by the presence of terminal alkyl fluorine atom. The ring hydroxylated metabolites shown are JWH-018 4-OH (3), JWH-018 5-OH (4), JWH-018 6-OH (5), and JWH-018 7-OH (6) and alkyl side chain metabolites are JWH-018 -OH (7), JWH-018 -COOH (8), JWH-018 -1-OH (9), and AM2201 -1-OH (10).
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Materials and Methods
Materials. All chemicals used for this study were of reagent grade or higher. Analytical standards for JWH-018, AM2201, and their hydroxylated and carboxylated metabolites (Fig. 1) were kindly provided by Cayman Chemical Company (Ann Arbor, MI). cDNA-expressed human recombinant cytochrome P450 enzymes (BD-Supersomes), pooled human liver microsomes (HLM) (50-donor pool), and the NADPH-regenerating system (20 mM NADP ϩ , 60 mM glucose 6-phosphate, 60 mM MgCl 2 , and 100 U/ml glucose 6-phosphate dehydrogenase) were purchased from BD Gentest (Woburn, MA). Optima LC-mass spectrometry-grade acetonitrile and ethanol were purchased from Thermo Fisher Scientific (Waltham, MA). Reagent-grade formic acid (99% pure) was purchased from Acros Organic (Fairlawn, NJ). Deionized water was purified to 18.2 M⍀-cm resistivity using a PURELAB Ultra laboratory water purification system (ELGA, Woodridge, IL). All other chemicals and reagents, unless otherwise specified, were purchased from SigmaAldrich (St. Louis, MO).
For CB 1 receptor binding and activity assays, all drugs, with the exception of -1-OH metabolites of JWH-018 and AM2201 were diluted to a concentration of 10 Ϫ2 M with 100% ethanol and stored at Ϫ20°C. The -1-OH metabolites of JWH-018 and AM2201 were diluted to a concentration of 10
Ϫ2
M with 100% dimethyl sulfoxide and stored at Ϫ20°C. ⌬ 9 -THC was supplied by the National Institute on Drug Abuse (Bethesda, MD). 5-(1,1-Dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol (CP-55,940) and (6aR,10aR)-3-(1-methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran (O-2050) were purchased from Tocris Bioscience (Ellisville, MO). GTP␥S and GDP were purchased from EMD Chemicals (Gibbstown, NJ) and Sigma-Aldrich, respectively. Both chemicals were diluted to a stock concentration of 10 Ϫ2 M with water and stored at Ϫ20°C. Equipment. Kinetic analysis was performed using an API-4000 Q TRAP tandem mass spectrometer (AB SCIEX, Framingham, MA) interfaced with an Series 1200 quaternary liquid chromatography system (Agilent Technologies, Santa Clara, CA). Analyst software (version 1.5; AB SCIEX) was used to control the overall operation of the high-performance liquid chromatography system and the mass spectrometer. For CB 1 receptor binding and intrinsic activity assays, bound radioactivity was determined by an LS6500 liquid scintillation spectrophotometer (Beckman Coulter, Brea, CA) .
Screening of JWH-018 and AM2201 Using Human Recombinant P450 Isoforms and Pooled Human Liver Microsomes. To examine the metabolism of JWH-018 and AM2201, cDNA-expressed human recombinant cytochrome P450 enzymes (2 pmol, CYP1A2, -2C9, -2C19, -2D6, -2E1, and -3A4; BD Supersomes) and pooled HLM (50 g) from a 50-donor pool were assayed for activity toward these compounds. Substrates (JWH-018 and AM2201, 10 M, final concentration) were added in ethanol and allowed to dry at ambient temperature. Protein was added in the presence of 0.1 M KPO 4 (final concentration) buffer, pH 7.4, with an NADPH-regenerating system (solution A: 20 mM NADP ϩ , 60 mM glucose 6-phosphate, and 60 mM MgCl 2 ; solution B: 100 U/ml glucose 6-phosphate dehydrogenase) to ensure sufficient NADPH to enable cytochrome P450-mediated reactions. Controls omitting the substrate, protein, and NADPH were included with each assay. To determine whether oxidoreductase (OR) and cytochrome b 5 metabolize JWH-018 and AM2201, a 10 M final concentration of each was incubated in presence of OR and cytochrome b 5 (50 g) under similar assay conditions. The total reaction volume was 50 l, and all incubations were performed in triplicate. Reactions were initiated by the addition of the NADPH-regenerating system, incubated at 37°C for 90 min, and terminated by addition of an equal volume of ethanol. Before LC-MS/MS analysis, protein and other particulates were precipitated by centrifugation at 20,800g for 5 min.
Steady-State Enzyme Kinetic Assays. For kinetic analysis, incubation conditions were optimized for time and protein concentration. All reactions were performed within the linear range of metabolite formation and less than 5% of substrate was consumed during the course of the reaction (data not shown). Other than substrate concentrations and incubation times, reaction mixture compositions and analytical methods were identical to those described for screening assays above. Kinetic parameters were determined by incubating recombinant CYP1A2, CYP2C9, CYP2C19 (2 pmol each), and CYP2D6 (4 pmol) in the presence of various concentrations of substrate (JWH-018 and AM2201, 0.05-100 M) for 10 min at 37°C for CYP1A2, CYP2C9, and CYP2C19 and 20 min at 37°C for CYP2D6. For reactions using HLM, various concentrations of substrates (JWH-018 and AM2201, 0.05-100 M) were incubated with 75 g of HLM protein for 20 min at 37°C.
LC-MS/MS Analysis. Quantification of analytes of interest was performed using positive ion electrospray ionization LC-MS/MS methods developed previously for trace analysis of synthetic cannabinoid metabolites (Chimalakonda et al., 2011b; Moran et al., 2011) . For these studies, analytical standards (0.20 -100 ng/ml) were matrix-matched in pooled human urine void of synthetic cannabinoid contamination or in the final in vitro reaction mixture (ethanol-water-0.1 M phosphate buffer, pH 7.4, 50:30:20%). Analytes of interest were chromatographically separated as described previously under isocratic conditions using an Zorbax Eclipse XDB-C18 analytical column (150 ϫ 4.6 mm, 5 m; Agilent Technologies) heated to 40°C. Mobile phases consisted of 45% A (0.1% formic acid in water) and 55% B (0.1% formic acid in acetonitrile (Chimalakonda et al., 2011b; Moran et al., 2011) . The XDB-C18 analytical column was washed and reequilibrated between each injection by ramping mobile phase B to 95% and then returning the system to initial conditions. The TurboIonSpray source voltage was 2500 V, and source temperature was maintained at 600°C. Nitrogen gas pressures for the GS1 and GS2 source gases, curtain gas, and collision gases were 55.0 cm/s, 55.0 cm/s, 35.0 cm/s, and "high," respectively.
Confirmation of each metabolite was determined by including specific reaction monitoring (SRM)-information-dependent acquisitions (IDAs) to obtain enhanced product ion (EPI) spectra for each product. Molecule-specific parameters for SRM-IDA experiments are listed in Supplemental Table 1 . The SRM-IDA transition threshold that triggered EPI experiments was fixed at 500 cps. Resulting EPI mass spectra for quality control and unknown specimens were library-matched against stored EPI mass spectra as reported previously (Chimalakonda et al., 2011b; Moran et al., 2011) or obtained from newly synthesized analytical standards to ensure that similar urinary metabolites that may interfere with analysis were fully resolved. Supplemental Figure 1 shows the mass spectra used to confirm the presence of the -1-OH metabolite of AM2201 in each reaction and identifies the appropriate molecular ion ([MH ϩ ], m/z 376) and expected product ions characteristic of aminoalkylindoles (m/z 127 and 155). In addition to mass spectra comparisons, all metabolic products were confirmed by matching retention times of analytical standards. LC-MS/MS conditions have previously been shown to resolve each of the metabolites assayed from their corresponding conjugates (Chimalakonda et al., 2011a) .
␤-Glucuronidase Treatment of Subject Samples. To evaluate human urinary metabolic profiles, 40 l of human urine were incubated in the presence and absence of ␤-glucuronidase (bovine liver, type B-10; SigmaAldrich) at 37°C, with constant shaking for 60 min, by adding 160 l of 0.1 M sodium acetate buffer, pH 5.0, containing ␤-glucuronidase (1.6 U/l final concentration). After incubations, 100 l of the final reaction mixture was spiked with deuterium-labeled internal standards available for -OH and -COOH metabolites (100 ng/ml final concentrations) before LC-MS/MS analysis.
Kinetic Data Analysis. Curve-fitting and statistical analyses were conducted using GraphPad Prism (version 4.0b; GraphPad Software Inc., San Diego, CA). Kinetic constants were obtained by fitting experimental data to kinetic models using the nonlinear regression (Curve Fit) function.
The fit of the data for each model was assessed from the S.E., 95% confidence intervals, and R 2 values. Kinetic curves were also analyzed as Eadie-Hofstee plots to support kinetic models. Kinetic constants are reported as the mean Ϯ S.E. of triplicate experiments. nitrogen, and stored at Ϫ80°C. B6SJL mice were chosen as a model system because the sequence similarity between mice and human CB 1 receptor is Ͼ85%, and B6SJL mice have been used extensively by our laboratory to study CB 1 receptor-mediated pharmacology of various cannabinoids (Brents et al., 2011 (Brents et al., , 2012 . Crude membrane homogenates were prepared on the basis of established methods (Prather et al., 2000) . Brains were thawed on ice, pooled, and suspended in ice-cold homogenization buffer (50 mM HEPES, pH 7.4, 3 mM MgCl 2 , and 1 mM EGTA). Suspended brains were then subjected to 10 complete strokes using a 40-ml Dounce glass homogenizer and centrifuged at 40,000g for 10 min at 4°C. Supernatants were discarded, and pellets were resuspended in ice-cold homogenization buffer, homogenized, and centrifuged similarly two more times. After the final centrifugation step, pellets were resuspended in ice-cold 50 mM HEPES, pH 7.4, to a concentration of approximately 2 mg/ml and aliquoted for storage at Ϫ80°C. Protein concentration was determined using BCA Protein Assay (Thermo Fisher Scientific).
CB 1 Receptor Binding: Competition Binding Assay. Mouse brain membrane homogenates (50 g, containing a relatively pure source of CB 1 receptors) were incubated with a 0.2 nM concentration of the radiolabeled cannabinoid agonist [
3 H]CP-55,940 for 90 min at room temperature in an assay buffer containing 5 mM MgCl 2 , 50 mM Tris, 0.05% bovine serum albumin (BSA), and increasing concentrations (0.1 nM-10 M) of JWH-018, AM2201, and their -OH (terminal position on the pentyl side chain) and -1-OH and -COOH (5-(3-(1-naphthoyl)-1H-indol-1-yl)-pentanoic acid) metabolites ( Fig. 1 ). Assays were performed in triplicate, in a final volume of 1.0 ml, as described previously (Shoemaker et al., 2005 -55,212-2) . Specific binding was calculated by subtracting nonspecific from total binding. Reactions were terminated by quick filtration through Whatman GF/B glass fiber filters, followed by five washes with an ice-cold buffer containing 50 mM Tris and 0.05% BSA. Filters were punched out into 7-ml scintillation vials and immersed in 4 ml of ScintiVerse BD Cocktail scintillation fluid. After overnight extraction, bound radioactivity was determined by liquid scintillation spectrophotometry. Specific binding is expressed as a percentage of binding occurring in vehicle samples (binding in the absence of any competitor).
CB 1 Receptor Functional Assay: [
35 S]GTP␥S Binding. [ 35 S]GTP␥S binding was performed as described previously with minor modifications (Prather et al., 2000) . Each synthetic cannabinoid or metabolite was incubated with 25 g of mouse brain membrane homogenates, 10 mM GDP, 0.1 nM [ 35 S]GTP␥S, and assay buffer (20 mM HEPES, 10 mM MgCl 2 , 100 mM NaCl, 20 U/l adenosine deaminase, and 0.05% BSA). Assays were performed in triplicate in a final volume of 1 ml for 30 min at 30°C. Total binding was defined as the amount of radioactivity observed when 0.1 nM [
35 S]GTP␥S was incubated in the absence of any cannabinoid. Nonspecific binding was defined as the amount of [
35 S]GTP␥S binding remaining in the presence of 10 M nonradioactive GTP␥S. Specific binding was calculated by subtracting nonspecific from total binding. Reactions were terminated by quick filtration through Whatman GF/B glass fiber filters, followed by five washes with an ice-cold buffer containing 20 mM HEPES and 0.05% BSA. Filters were punched out into 7-ml scintillation vials and immersed in 4 ml of ScintiVerse BD Cocktail scintillation fluid. After overnight extraction, bound radioactivity was determined by liquid scintillation spectrophotometry. The amount of specific [
35 S]GTP␥S binding produced by each drug was normalized by expressing the G-protein activation for each compound as a percentage of binding produced by the full CB receptor agonist CP-55,940.
Statistical Analysis. Curve fitting and statistical analyses for competition binding experiments were performed using GraphPad Prism. The ChengPrusoff (Cheng and Prusoff, 1973) 35 S]GTP␥S binding produced by each drug, relative to that produced by the full CB receptor agonist CP-55,940. Data are expressed as means Ϯ S.E.M. A one-way ANOVA, followed by a Newman-Keuls multiple comparison post hoc test, was used to determine statistical significance (P Ͻ 0.05) between the groups. All statistical calculations were performed using GraphPad Prism.
Results
To begin assessing the physiological relevance of HLM reactions, metabolites produced in vitro were qualitatively compared with metabolic products excreted in human urine collected from individuals suspected of using JWH-018 or AM2201 (Fig. 2) . Consistent with FIG. 2 . LC chromatograms of the hydroxyl and carboxyl metabolites of JWH-018 and AM2201 in human liver microsomes and human urine. Resulting chromatographs produced from incubation of 10 M JWH-018 (A) and AM2201 (B) with 75 g of HLM as explained under Materials and Methods and from representative human urine collected after suspected use of JWH-018 (C) or AM2201 (D) are shown. Chromatographs shown were generated after treatment of the urine with ␤-glucuronidase as described under Materials and Methods. The numbers above the chromatographic peaks correspond to the hydroxylated and carboxylated metabolites of JWH-018 and AM2201 shown in Fig. 1 . Concentrations of the respective metabolites in B are as follows: JWH-018 -OH (8.53 ng/ml), JWH-018 -COOH (4.7 ng/ml), and JWH-018 -1-OH (9.6 ng/ml). Concentrations of respective metabolites in D are as follows: JWH-018 -OH (19.6 ng/ml), JWH-018 -COOH (9.2 ng/ml), and JWH-018 -1-OH (1.06 ng/ml). Different color tracings are representative of the SRM experiments (Supplemental Table 1 ) used to detect analytes 1 to 10 (Fig. 1) previous reports, JWH-018 and AM2201 appear to be metabolized similarly to produce several ring and alkyl side chain oxidized metabolites that are excreted in human urine as glucuronic acid conjugates (Chimalakonda et al., 2011b; Moran et al., 2011) . It also appears that AM2201 readily undergoes cytochrome P450-mediated oxidative dehalogenation to produce common metabolites with JWH-018, whereas the -1-OH metabolites of each synthetic cannabinoid are distinct. In vitro reactions led to the formation of three different indole ring-substituted oxidized metabolites (Fig. 2) , but these metabolites were not detected in the human specimens. The physiological significance of this finding remains to be determined. Although it is difficult to extrapolate urinary concentrations to toxicological endpoints, data identify the pentyl alkyl side chain present in both JWH-018 and AM2201 (Fig. 1) as the primary site for P450-mediated oxidation in humans.
To further assess metabolic pathways responsible for JWH-018 and AM2201 oxidation, six human recombinant P450 isoforms listed in Fig. 3 were screened for their ability to mediate JWH-018 and AM2201 oxidation. All screening assays used a 10 M substrate concentration to maximize the potential for identifying all oxidized products. Reaction velocities were estimated by determining the concentration of the -OH, -COOH, -1-OH, and indole ring-oxidized metabolites (Fig. 1) using established LC-MS/MS methods, previously validated for trace level quantification (Chimalakonda et al., 2011b; Moran et al., 2011) . After normalizing reaction velocities to hepatic abundance (Rowland-Yeo et al., 2003) , CYP1A2 and CYP2C9 exhibited the most activity toward JWH-018 and AM2201 oxidation, whereas much less contribution from CYP2C19, 2D6, 2E1, and 3A4 was observed (Fig. 3) . No interfering products were identified in negative control reactions omitting either substrates or cofactor (data not shown). Incubation of JWH-018 with OR and cytochrome b 5 led to the formation of the JWH-018 5-OH metabolite (5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (ϳ12 nM, data not shown). The concentration of unidentified-OH metabolites of JWH-018 and AM2201 reported in Supplemental Tables 2 to 5 was estimated from standard responses obtained using the JWH-018 -OH analytical standard.
Oxidized products produced during reactions with each recombinant protein (Fig. 4) were also qualitatively compared with metabolic profiles observed in human specimens (Fig. 2) . Similar to metabolic profiles observed in human urine specimens, CYP1A2 reactions with JWH-018 produced the -OH, -COOH, and -1-OH metabolites along with a single indole ring-oxidized metabolite (Fig. 4A) . Of interest, CYP1A2 is the only isoform that produced the -COOH derivative in the presence of JWH-018. CYP2C9 produced equivalent levels of the -OH and -1-OH metabolites (Fig. 4B) , whereas CPY2C19 predominantly catalyzed the formation of the -1-OH metabolite (Fig. 4C) . CYP2D6 catalyzes the formation of several indole ring-oxidized derivatives along with the formation of the alkyl side chain oxidized metabolites (Fig. 4D) .
CYP1A2, CYP2C9, and CYP2C19 all mediated oxidative dehalogenation reactions in the presence of AM2201 to form the -OH and the -COOH metabolites (Fig. 4, E-G) , but, in addition, the -1-OH derivative of AM2201 along with an unidentified-OH metabolite was also formed. In general, incubation of AM2201 with CYP2D6 led to overall lower metabolite formation in comparison with CYP1A2, CYP2C9, and CYP2C19, but sufficient activity led to the identification of -OH and the unidentified-OH derivatives as major AM2201 metabolites (Fig. 4H) .
Kinetic Analysis. Screening data indicate a significant role for CYP2C9 and CYP1A2 in the oxidation of JWH-018 and AM2201. Therefore, the kinetic analysis of JWH-018 and AM2201 oxidation in HLM was compared with that of recombinant CYP2C9 and CYP1A2 to further assess the overall contribution of these enzymes in synthetic cannabinoid metabolism. The formation of -OH and -1-OH metabolites of JWH-018 in HLM exhibited saturable hyperbolic kinetics consistent with a Michaelis-Menten kinetic profile (Table 1 ; Supplemental Fig. 3A) , whereas the kinetic profile for the formation of indole ring-oxidized (metabolites 3-6; Fig. 1 ) and an unidentified-OH derivative of JWH-018 exhibited Michaelis-Menten or Hill activation kinetics, respectively (Supplemental Table 2 ; Supplemental Fig. 6A ).
Kinetic analysis of JWH-018 oxidation with human recombinant CYP1A2 exhibited classic Michaelis-Menten kinetics for the formation of -OH and -1-OH derivatives, with high affinity (low apparent K m values ranging from 4.7-5.3 M) and high capacity (V max ϭ 833-1438 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ), whereas the kinetic profile for the formation of the -COOH metabolite with CYP1A2 exhibited substrate inhibition (SI). The -OH and -1-OH metabolite formation with recombinant CYP2C9 exhibited activation kinetics fitting the Hill equation, with high affinity (low apparent K m ϭ 0.81-1.3 M) and high capacity (V max ϭ 487-835 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ) (Table 1 ; Supplemental Fig. 4 ). HLM reactions with AM2201 followed either classic MichaelisMenten kinetics or a biphasic kinetic profile ( Fig. 3B) . Formation of the -COOH metabolite common with JWH-018 and the distinct -1-OH metabolite of AM2201 followed Michaelis-Menten kinetics, whereas formation of the -OH metabolite exhibited a biphasic kinetic profile, consistent with microsomal enzyme preparations in which more than one type of enzyme is responsible for the formation of product.
Kinetic analysis of AM2201 oxidation with human recombinant CYP1A2 exhibited classic Michaelis-Menten kinetics for the formation -OH, -COOH, and -1-OH metabolites, with high affinity (low apparent K m values ranging from 3.6 -6.6 M) and high capacity (V max ϭ 90 -319 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ). The -OH and -COOH metabolite formation with recombinant CYP2C9 exhibited Michaelis-Menten kinetics with high affinity (low apparent K m ϭ 2.4 -7.2 M) and high capacity (V max ϭ 266 -309 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ). However, the -1-OH metabolite formation with CYP2C9 followed substrate inhibition kinetics with high affinity (low apparent K m ϭ 7.2 M) and high capacity (V max ϭ 122 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ) ( Table 2 ; Supplemental Fig. 5) .
Although screening data indicate that the contribution of CYP2C19 and CYP2D6 in the hepatic metabolism of JWH-018 and AM2201 is minimal (Fig. 2) , actual contributions can only be assessed through detailed kinetic evaluations. Largely, the kinetic profiles observed during either JWH-018 or AM2201 oxidation to form the -OH, -1-OH, and -COOH metabolites with recombinant CYP2C19 exhibited atypical kinetics. The reason for this is unknown and is a subject of further study. All K m and V max values reported in Table 1 are approximated. Concentrations of oxidized metabolites formed via CYP2D6 oxidation were low, but these reactions did exhibit classic Michaelis-Menten kinetics for the formation of -OH and -1-OH derivatives with high affinity (low apparent K m ϭ 2.8 -3.2 M) and low capacity (V max ϭ 26 -43 pmol of product ⅐ min Ϫ1 ⅐ nmol protein Ϫ1 ) when JWH-018 was used as the substrate (Table 1) . When AM2201 was used, the same kinetic profiles were observed for each Table 2 are approximated.
To determine the major biotransformation pathways responsible for JWH-018 and AM2201 oxidation in human liver microsomes, intrinsic clearance (CL int ) (microlitres per minute per milligram of protein) was estimated for each metabolite. As shown in Table 3 , more than 90% of JWH-018 is metabolized in human liver microsomes to form the 5-OH, 6-OH, -OH, and -1-OH metabolites. The intrinsic clearance of AM2201 follows a slightly different pathway, in which approximately 85% is metabolized to only the -OH and -COOH metabolites. The -1-OH and the unidentified-OH metabolites are formed to a much lesser extent.
To better assess the relative contribution of each cytochrome P450 isozyme, CL int values (microliters per minute per nanomole of P450) for the formation of indole ring, alkyl side chain, and unidentified-OH metabolites of JWH-018 and AM2201 with recombinant CYP1A2, -2C9, -2C19, and -2D6 were calculated and normalized to hepatic abundance (Rowland-Yeo et al., 2003; Proctor et al., 2004) . The metabolic fraction (f m, CYP ) calculations presented in Table 4 identify CYP2C9 as the primary isozyme responsible for the metabolism of JWH-018 to its -OH and -1-OH derivatives (f m, 2C9 ϭ ϳ0.83-0.90 and 0.48 -0.62, respectively); whereas CYP1A2 appears to be responsible for -COOH formation (f m, 1A2 ϭ 1). CYP2C9 and CYP1A2 also appear to play an important role in oxidizing AM2201 to the corresponding -OH, -1-OH, and -COOH metabolites with f m, 2C9 ranging from 0.48 to 0.76 and f m, 1A2 ranging from 0.11 to 0.49 (Table 5) . Both CYP1A2 and CYP2C9 also appear to catalyze the formation of the unidentified-OH metabolite of AM2201 (f m, 1A2 ϭ ϳ0.42-0.56 and f m, 2C9 ϭ ϳ0.29 -0.40), but the physiological significance of this metabolite remains to be determined. CYP2C19 and CYP2D6 contributions to JWH-018 and AM2201 hepatic oxidation seem to be negligible (Tables 4 and 5 ). However, CYP2C19 catalyzed some formation of the unidentified-OH metabolite of AM2201 (f m, 2C19 ϭ 0.19) (Supplemental Table 5 ).
Pharmacological/Toxicological Evaluations: CB 1 Receptor Binding and Intrinsic Activity. To begin understanding the pharmacological and/or toxicological consequences of synthetic cannabinoid metabolism, we used CB 1 receptor binding and intrinsic activity assays to determine whether cytochrome P450-mediated biotransformation led to the formation of biologically active intermediates or whether oxidation terminated activity at the cannabinoid receptor. We have previously reported the binding affinity for several of the indole ringoxidized metabolites and the fact that the -COOH metabolite of JWH-018 does not bind to the CB 1 receptor (Brents et al., 2011) . However, the primary metabolites, with the exception of -OH derivative, have never been investigated for CB 1 receptor binding and intrinsic activity assays. Studies presented here are similar to our previous report (Brents et al., 2011) . In addition, these studies showed that JWH-018, AM2201, and their -OH and -1-OH metabolites, but not the -COOH metabolite, bind to the CB 1 receptor with high affinity. JWH-018, AM2201, and its -OH and -1-OH metabolites showed high affinity (K i ϭ ϳ0.4 -35 nM), resulting in complete displacement of [ 3 H]CP-55,940 from the CB 1 receptor (Fig. 5, A and B). The relative rank order of binding affinity for all the compounds tested was AM2201 ϭ JWH-018 Ͼ JWH-018/AM2201 -1-OH ϭ JWH-018 -OH. More importantly, the CB 1 receptor affinity was higher for JWH-018 and AM2201, and similar for -OH and -1-OH derivatives of each synthetic cannabinoid (Fig. 5 ) compared with the affinity of ⌬ 9 -THC (15.3 nM) for CB 1 receptors (Brents et al., 2011) . The ability of JWH-018, AM2201, and -OH, -1-OH, and -COOH metabolites to activate G-proteins after binding to the CB 1 receptors was investigated using the [ 35 S]GTP␥S binding assay (Fig. 6A) . A receptor saturating concentration (10 M) of CP-55,940, ⌬ 9 -THC, JWH-018, AM2201, and their -OH, -1-OH, and -COOH derivatives was used to determine a measure of maximal efficacy produced by activation of CB 1 receptors in mouse brain membranes. CP-55,940, JWH-018, AM2201, and JWH-018 -OH and -1-OH and AM2201 -1-OH metabolites produced a similar level of G-protein activation (Fig. 6A) , and in this assay appear to act as full CB 1 receptor agonists, similar to CP-55,940. The intrinsic efficacy (G-protein activation) of JWH-018, AM2201, and their -OH and -1-OH metabolites was statistically greater ( p Ͻ 0.05) than that of the partial agonist and principal psychoactive ingredient of marijuana, ⌬ 9 -THC (Fig. 6A) . As might be expected on the basis of poor CB 1 receptor affinity, the -COOH derivative of JWH-018 did not stimulate G-proteins (Fig. 6A ). Coincubation with a receptor saturating concentration (1 M) of the CB 1 receptor antagonist O-2050 significantly attenuated G-protein activation elicited by all compounds examined, strongly suggesting CB 1 receptor selectivity of these compounds (Fig. 6B) . Of importance, O-2050 demonstrated no significant effects on basal G-protein activity when administered alone (data not shown). The CB 1 receptor activation elicited by -OH and -1-OH metabolites indicates that cytochrome P450-mediated oxidation of JWH-018 and AM2201 leads to the formation of potent and efficacious metabolites that retain significant affinity and activity at CB 1 receptors.
Discussion
In 2005, synthetic cannabinoid products, marketed as K2/Spice emerged as new drugs of abuse and have been gaining popularity worldwide ever since. Today, there are significant public health concerns related to these psychoactive drugs of abuse with one in nine high school students admitting use of K2 (Hu et al., 2011) . Furthermore, there is increasing morbidity and mortality reports related to these potent human cannabinoid receptor agonists, which were originally synthesized to study CB 1 and CB 2 receptors and their potential antiemetic and pain-relieving therapeutic properties. There is an urgent need to elucidate the pharmacology of these substances in humans. Before pharmacokinetic and pharmacodynamic properties can be adequately studied in humans, metabolic pathways leading to metabolism and elimination and pathways leading to the generation of biologically active metabolites must be delineated. Therefore, the purpose of the present study was to identify specific P450 isoforms responsible for JWH-018 and AM2201 metabolism and to compare the relative affinity and intrinsic activity of the primary human metabolites at CB 1 receptors.
After the discovery of ⌬ 9 -THC as the primary psychoactive constituent of cannabis, several studies (Wall et al., 1983; Bornheim et al., 1992; Watanabe et al., 1995 Watanabe et al., , 2007 Bland et al., 2005) demonstrated that ⌬ 9 -THC is primarily metabolized to a single active metabolite, 11-OH-⌬ 9 -THC, by CYP2C9 and to various inactive oxidized products by CYP3A4. In contrast, this study identifies CYP2C9 and CYP1A2 as primary P450 isoforms involved in the oxidation of the psychoactive synthetic cannabinoids JWH-018 and AM2201. In vitro HLM incubation of JWH-018 and AM2201 primarily led to the formation of alkyl side chain-oxidized metabolites that the mirrored metabolic patterns observed in human urine specimens collected after suspected JWH-018 or AM2201 use. Indole ring-oxidized metabolites and two unidentified hydroxylated metabolites were also produced in vitro, but the physiological significance of these findings remains to be determined. Consistent with data presented in this report, studies have consistently identified the alkyl side chain-oxidized metabolites as the primary circulating and thus potentially bioavailable derivatives (Kacinko et al., 2011) . Human studies have also demonstrated that glucuronic acid conjugation is required for urinary excretion (Chimalakonda et al., 2011b; Moran et al., 2011) of synthetic cannabinoids. The present study identified CYP2C9 and CYP1A2 as the primary enzymes involved in the hepatic oxidation of JWH-018 and AM2201. CYP2C9 is one of the major human polymorphic enzymes, with the most common allelic variants showing reduced rates of metabolism toward substrates (Ortiz de Montellano, 1995) . This enzyme is highly expressed both in the liver and intestine (Paine et al., 2006) and is involved in the metabolism of ⌬ 9 -THC and approximately 16% of drugs in current clinical use, such as fluoxetine, escitalopram, citalopram, lithium, valproic acid, aripiprazole, and risperidone (Ortiz de Montellano, 1995) . Given the high abundance of CYP2C9 in the intestine, it is anticipated that this isoform will be intricately involved in the intestinal metabolism of synthetic cannabinoids taken orally, as well as other routes of exposures. Consideration of oral routes of exposure is important because we have previously shown that ingestion of JWH-018 can lead to rapid and severe toxicity in humans (Lapoint et al., 2011) . Toxic drug-drug interactions are also an important concern for public health officials, especially because hepatic intrinsic clearance associated with CYP2C9 metabolism is greater than 50%. CYP1A2 also contributed significantly to the hepatic metabolism of JWH-018 and AM2201. This isozyme is involved in the biotransformation of 5 to 10% of drugs in current clinical use and is known to be differentially expressed in humans, suggesting polymorphic control of enzyme activity (Ortiz de Montellano, 1995) . Therefore, individuals with significantly lower expression of CYP1A2 would be predicted to have a decreased capacity for synthetic cannabinoid detoxification and may be at increased risks for adverse consequences.
Although the involvement of CYP2C19 and CYP2D6 in the overall hepatic metabolism of JWH-018 and AM2201 is minimal, the physiological importance of these enzymes in other tissues remains to be FIG. 5 . JWH-018 and its -OH and -1-OH metabolites (A) and AM2201 and its -1-OH metabolite (B) bind the CB 1 receptor with nanomolar affinity. JWH-018, AM2201, and -OH and -1-OH metabolites, but not the -COOH metabolite, completely displaced the radiolabeled cannabinoid [ determined. For example, it is well established that CYP2D6 is involved in the metabolism of many central nervous system-acting drugs (Ingelman-Sundberg, 2005) and that this P450 is one of the major mixed-function oxidases highly expressed in cerebral cortex, hippocampus, and cerebellum, regions known for high expression of CB 1 receptors (Meyer et al., 2007) . CYP2D6 is highly polymorphic, with more than 80 variant alleles identified to date, including the nonfunctional CYP2D6*4 null allele, present in 12 to 21% of whites (Ingelman-Sundberg, 2005) . Of importance, CYP2D6 is known to metabolize the endocannabinoid anandamide (Snider et al., 2008) , which suggests that this enzyme may also interact with other synthetic cannabinoids like JWH-018 and AM2201 in the brain. Although speculative, data presented in this report suggest that CYP2D6 may be critical in controlling brain concentrations of parent synthetic cannabinoids and their active metabolites.
Another critical finding presented in this study is that JWH-018, AM2201, and their major hydroxylated metabolites produced in vitro and in humans exposed to these synthetic cannabinoids bind to and activate CB 1 receptors with nanomolar affinity. These data are in stark contrast to binding data for ⌬ 9 -THC. All ⌬ 9 -THC metabolites, except 11-OH-⌬ 9 -THC, are inactivated by oxidative metabolism, which prevents further CB 1 receptor activation (Adams and Martin, 1996) . The higher affinity, potency, and efficacy of JWH-018 and AM2201, coupled with its potential metabolism to a number of equally active metabolites, suggests that both acute and chronic effects of K2 may be intensified compared with a similar level of exposure to marijuana. In relation to ⌬ 9 -THC, the results presented herein suggest that differences in synthetic cannabinoid metabolism may lead to differential pharmacokinetic and pharmacodynamic properties and might offer explanations for the widely observed adverse clinical manifestations of synthetic cannabinoid abuse.
Data from the present study provide critical missing information related to the metabolism and toxicological properties of K2 parent compounds and their human metabolites, including mechanism(s) of action at cannabinoid receptor subtypes. The findings of the present study provide the groundwork for studying potential mechanisms of toxicity in humans and establish a basis for developing widely available screening tools for detecting K2 abuse. Of importance, data demonstrate that the synthetic cannabinoid compounds have a greater toxicity potential in comparison with ⌬ 9 -THC because of their unique metabolic profiles and drug/metabolite binding characteristics, which may predispose humans to a constellation of serious adverse effects reported after K2 use. and hepatic abundance values of specific P450s (Proctor et al., 2004; Rowland-Yeo et al., 2003) are given in nmoles/mg protein, respectively.
